Supplementation of a Standardized Extract from Phyllanthus emblica Improves Cardiovascular Risk Factors and Platelet Aggregation in Overweight/Class-1 Obese Adults
Supplementation of a Standardized Extract from Phyllanthus emblica Improves Cardiovascular Risk Factors and Platelet Aggregation in Overweight/Class-1 Obese Adults
复制标题
DOI：
10.1089/jmf.2014.0178
复制
发表时间：
2015-04-01
影响因子：
2.4
通讯作者：
Roy, Sashwati
中科院分区：
文献类型：
--
作者：
Khanna, Savita;Das, Amitava;Roy, Sashwati
本研究（clinicaltrials.gov NCT01858376）的目的是确定口服补剂标准甘油三叶提取物（CAPROS((R))）对美国超重成人受试者心血管疾病（CVD）危险因素的影响。超重/ 1级肥胖（身体质量指数：25-35）的成人受试者每天服用500 mg CAPROS补充剂，持续12周。研究设计包括两次基线访问，随后是12周的补充，然后是2周的洗脱。在所有访问中，外周静脉血在柠檬酸钠管中采集。脂质谱测量显示，与平均基线就诊相比，补充CAPROS 12周后，计算出的低密度脂蛋白胆固醇和总胆固醇/高密度脂蛋白显著下降。补充12周后，循环高敏C反应蛋白（hs-CRP）水平显著降低。此外，在补充12周后，ADP和胶原诱导的血小板聚集均显著下调。总体而言，该研究表明，口服CAPROS补充剂可能通过降低多种全球心血管疾病危险因素，为超重/ 1级肥胖成人提供有益效果。
The objective of this study (clinicaltrials.gov NCT01858376) was to determine the effect of oral supplementation of a standardized extract of Phyllanthus emblica (CAPROS((R))) on cardiovascular disease (CVD) risk factors in overweight adult human subjects from the US population. Overweight/Class-1 obese (body-mass index: 25-35) adult subjects received 500 mg of CAPROS supplement b.i.d for 12 weeks. The study design included two baseline visits followed by 12 weeks of supplementation and then 2 weeks of washout. At all visits, peripheral venous blood was collected in sodium citrate tubes. Lipid profile measurements demonstrated a significant decrease in calculated low-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein following 12 weeks of CAPROS supplementation when compared to averaged baseline visits. Circulatory high-sensitivity C reactive protein (hs-CRP) levels were significantly decreased after 12 weeks of supplementation. In addition, both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation. Overall, the study suggests that oral CAPROS supplementation may provide beneficial effects in overweight/Class-1 obese adults by lowering multiple global CVD risk factors.